| Name | Title | Contact Details |
|---|---|---|
Helen Shin |
Director, Human Resources | Profile |
Simon Pimstone |
Chief Executive Officer | Profile |
Shelley McCloskey |
Senior Vice President of Human Resources | Profile |
Respitech Medical Inc is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nobest Inc is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Medica is a non-profit health plan that serves communities in Minnesota, Iowa, Kansas, Missouri, Nebraska, North Dakota, Oklahoma, South Dakota and Wisconsin — the heart of America. As a company, we empower communities by listening to their voices, learning about community needs, and devoting time and resources to help. Medica partners with the communities it serves in many ways, including the Medica Foundation, a nonprofit, charitable grant-making foundation. The Medica Foundation, which provides more than $1 million in grants annually, generally seeks to fund community-based programs and initiatives that can provide sustainable, measurable improvements in the availability, access and quality of health care. To be the trusted health plan of choice for customers, members, partners and our employees. To be trusted in the community for our unwavering commitment to high quality, affordable health care.
WIL Research Company, Inc. is a privately held global Contract Research Organization that provides product safety toxicological research, bioanalytical, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries as well as manufacturing support for clinical trials.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.